Sakakibara-Konishi J, Kitai H, Ikezawa Y, Hatanaka Y, Sasaki T, Yoshida R, Chiba S Matsumoto S, Goto K, Mizugaki H, Shinagawa N. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer. Clin Lung Cancer. 2019, 20(5):e555-e559.
Naito T, Udagawa H, Umemura S, Sakai T, Zenke Y, Kirita K, Matsumoto S, Yoh K, Niho S, Tsuboi M, Ishii G, Goto K. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden. Lung Cancer. 2019, 138:35-42.
Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi S, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A. 2019, 116(20):10025-10030.
Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. Cancer Sci. 2018, 109(10):3149-3158.
Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles PP, Tsuchihara K, Matsumoto S, Shimada Y, Mimaki S, Ishii G, Ichikawa H, Nagatoishi S, Tsumoto K, Okuno Y, Yoh K, McDonald NQ, Goto K. A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat Commun. 2018, 9(1):625.
Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi Yamanaka T T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 2018, 36(14):1405-11
Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase Goto K K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano . Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. J Med Invest, 2017, 64(3.4):317-320
Hida T. Nokihara H. Kondo M. Kim Y. H. Azuma K. Seto T. Takiguchi Y. Nishio M Yoshioka H. Imamura F. Hotta K. Watanabe S. Goto K. Satouchi M. Kozuki T. Shukuya T. Nakagawa K. Mitsudomi T. Yamamoto N. Asakawa T. Asabe R. Tanaka T. Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet, 2017, 390(10089):29-39
Yoh K, Seto T, Satouchi Nishio M M, Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta Tsuchihara K K, Ishii G, Nomura S, Sato A, Ohtsu A, Ohe Y, Goto K. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med, 2017, 5(1):42-50.
Kohno T, Nakaoku T, Tsuta Tsuchihara K K, Matsumoto S, Yoh Goto K K. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res, 2015, 4(2):156-64
Udagawa H, Umemura S, Murakami I, Mimaki S, Makinoshima H, Ishii G, Miyoshi T, Kirita K, Matsumoto S, Yoh K, Niho S, Tsuchihara Goto K K. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis. Lung Cancer, 2018, 126:182-88.
Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, Niho S, Yoh K, Matsumoto S, Takahashi A, Morise M, Nakamura Y, Ochiai A, Nagai K, Iwakawa R, Kohno T, Yokota J, Ohe Y, Esumi H, Tsuchihara K, Goto K. Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis. J Thorac Oncol, 2014, 9(9):1324-1331
Goto K, Yoh K. Development of a Nationwide Screening Project and Clinical Trial for Lung Cancers with Rare Driver Mutations. 第11回日本臨床腫瘍学会学術集会、2013.8.29-31.
後藤功一、葉清隆：全国規模の遺伝子診断ネットワークによる希少肺癌スクリーニングシステムの構築と新薬開発への挑戦／Development of a Nationwide Screening Project and Clinical Trial for Lung Cancers with Rare Driver Mutations. 第72回日本癌学会学術総会、2013.10.3-5.
後藤功一：Individualized therapy based on target sequencing：遺伝子解析に基づいた個別化治療. 第72回日本癌学会学術総会、2013.10.3-5.
後藤功一：【International Symposium1】Development of a Nationwide Genomic Screening Project and Clinical Trial for Lung Cancers with Rare Driver Mutations 第54回日本肺癌学会総会、2013.11.21-22
後藤功一：Development of a Nationwide Genomic Screening Network and Clinical Trial for Lung Cancer with Rare Driver Mutations. 第12回日本臨床腫瘍学会学術集会、 2014.7.17-19
後藤功一：Development of a nationwide genomic screening network and clinical trial for lung cancer with rare driver oncogenes. 遺伝子異常を有する希少肺癌をターゲットにした遺伝子スクリーニングネットワークの構築と新薬開発への挑戦 ：第13回日本臨床腫瘍学会学術集会、2015.7.16-18
Goto K, A Nationwide Genomic Screening Project in Japan. 2nd Taiwan-Japan Academic Research Organization Workshop. Taipei TAIWAN May,28. 2016
Goto K. Development of a Nationwide Genomic Screen Project (LC-SCRUM-Japan) for the Establishment of Cancer Precision Medicine. The 10th NCC International Symposium. NCC Korea. 2016,6,15(招待講演)
後藤功一：Development of a Nationwide Genomic Screening Network and Clinical Trial for Lung Cancer with Rare Driver Oncogenes. 第14回日本臨床腫瘍学会、2016.7.28-30
Goto K, SCRUM Japan project a case of multi-center/ disciplinary effort to promote precision medicine in Japan. 5th US – Japan Clinical Trials in Oncology Workshop Washington, DC USA April.6 2017(招待講演)
後藤功一：Development of a Nationwide Genomic Screening Project (SCRUM-Japan) for the Establishment of Cancer Precision Medicine. 第15回日本臨床腫瘍学会学術集会、2017.7.27-29
海外在住の日本人研究者に向けた講演(招待講演) K Goto, SCRUM Japan project a case of multi-center/ disciplinary effort to promote precision medicine in Japan. 5th US – Japan Clinical Trials in Oncology Workshop Washington, DC USA April.6 2017
オンコマインDx Target Test マルチCDｘシステム
LC-SCRUM-Japanの遺伝子検査において、EGFR、ALK、ROS1陽性と判定された患者さんの検体を用いて、オンコマインDx Target Test マルチCDｘシステムの臨床性能試験を実施しました。その結果に基づいて、本診断システムが、切除不能な進行・再発の非小細胞肺がんの患者さんにおける4つの標的遺伝子（EGFR/ALK/ROS1/BRAF）の診断法として承認されました。
学会発表（海外）
Yoh K, Matsumoto S, Tsuchihara K, Kohno T, Ishii G, Tsuta K, Nishio M, Yamamoto N, Murakami H, Satouchi M, Nogami N, Seto T, Umemura S, Niho S, Ohmatsu H, Ohe Y, Yamanaka T, Goto K, The Lung Cancer Genomic Screening Project for Individualized Medicine in Japan (LC-SCRUM-Japan): Screening for RET and ROS1 fusions in advanced EGFR mutation-negative nonsquamous lung cancer and development of molecular targeted therapy. 50th ASCO. Chicago IL USA May.30-Jun4. 2014
Matsumoto S, Tsuchihara K, Yoh K, Y Zenke, Kohno T, Ishii G, Tsuta K, Umemura S, Niho S, Ohmatsu H, Ohe Y, Yamanaka T, Goto K, A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small lung cancers with rare driver mutations. 50th ASCO. Chicago IL USA May.30-Jun4. 2014
Yoh K, Matsumoto S, Tsuchihara K, Kohno T, Ishii G, Tsuta K, Nishio M, Yamamoto N, Murakami H, Satouchi M, Nogami N, Seto T, Umemura S, Niho S, Ohmatsu H, Ohe Y, Yamanaka T, Goto K, Nationwide genomic screening for RET fusion in advanced EGFR mutation-negative non-squamous lung cancer and development of molecular targeted therapy in Japan: LC-SCRUM-Japan. 2014 ESMO congress. Madrid. Spain 26 Sep – 30 Sep. 2014
Matsumoto S, Tsuchihara K, Yoh K, Y Zenke, Kohno T, Ishii G, Tsuta K, Umemura S, Niho S, Ohmatsu H, Ohe Y, Yamanaka T, Goto K. A nationwide genomic screening system in Japan for the development of molecular targeted therapies against non-small cell lung cancers with rare driver mutations. 2014 ESMO congress. Madrid. Spain 26 Sep – 30 Sep. 2014
Umemura S, Tsuchihara K, S Mimaki, Matsumoto S , Ishii G, Ohmatsu H , Niho S, Yoh K , Ohe Y, Goto K. High frequency of therapeutically relevant genomic alterations in advanced small cell lung cancer detected by targeted next-generation sequencing from small biopsy samples. 2014 ESMO congress. Madrid. Spain 26 Sep – 30 Sep. 2014
Matsumoto S, Yoh K, Seto T, T Yokoyama, Murakami H, Iwama E, Sugawara S, Ohe Y, Takeda K, Nishio M, Satouchi Shingyoji M M, Harada D, Okuyama T, Okamoto N, Kohno T, Tsuta K, Ishii G, Tsuchihara K, Goto K. Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan). ASCO, Chicago IL USA May.29-Jun2. 2015
Sugiyama E, Matsumoto S, Yoh K, Ohe Y, Seto T, Murakami H, Iwama E, Sugawara S, Yamada K, Takeda K, Hosomi Y, Saeki S, Yokoyama T, Nishio M, Satouchi M, Tsuta K, Kohno T, Ishii G, Tsuchihara K, Goto K, Clinicopathological features of patients with ROS1-rearranged advanced non-small cell lung cancer: LC-SCRUM-Japan. The European Cancer Congress 2015 Sep.25-29. 2015
Umemura S, Goto K, PI3K/AKT/mTOR. WCLC2015 16th World Conference on Lung Cancer. Denver COLORADO USA Sep6-8. 2015
Udagawa H, Umemura S, Mimaki S, Ishi G, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuchihara K, Goto K. Molecular profiling-based prognostic prediction of patients with advanced small-cell lung cancer. 52nd ASCO. Chicago IL USA Jun.3-7. 2016
Shimokawaji T, Sugiyama E, Matsumoto S, Yoh K, Shingyoji M, Ohashi K, Kato K, Aono H, Ohe Y, Sugawara S, Furuya N, Nakazaki H, Taima K, Watanabe H, Harada T, Sakamoto T, Ikemura S, Tsuchihara K, Goto K. Development of a nationwide genomic screening network for squamous cell lung cancer in Japan (LC-SCRUM-Japan). 52nd ASCO. Chicago IL USA Jun.3-7. 2016
Yokoyama T, Matsumoto S, Yoh K, Seto T, Murakami H, Iwama E, Ohe Y, Shingyoji M, Ohashi K, Takeda K, Hattori Y, Sugawara S, Saeki S, Fukui T, Nishio M, Kodani M, Kohno T, Tsuta K, Tsuchihara K, Goto K. Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan. 52nd ASCO. Chicago IL USA Jun.3-7. 2016
Matsumoto S, Yoh K, Kodani M, Ohashi K, Saeki S, Furuya N, Nishioka Y, Ohe Y, Seto T, Hayashi R, Kataoka Y, Fukui T, Sakamoto T, Ikemura S, Kohno T, Tsuta K, Tsuchihara K, Goto K. Detectability of druggable gene fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project (LC-SCRUM-Japan). ESMO 2016 Congress. Copenhagen Denmark 7-11 Oct. 2016. “
Sugiyama E, Matsumoto S, Kobayashi N, Aono H, Shingyoji M, Hotta K, Sekine A, Hara S, Furuya N, Nakagawa T, Nakazaki H, Harada T, Sugawara S, Takata S, Okamoto N, Taima K, Tomii K, Yoh K, Goto K. Clinical features of squamous cell lung cancer with targetable gene alterations in a nationwide genomic screening network in Japan (LC-SCRUM-Japan). ASCO. Chicago USA JUNE.2-6. 2017
Murakami H, Umemura S, Shinoda M, Shingyoji M, Ogawa Y, Takeda K, Nosaki K, Okamoto N, Aono H, Hara S, Kuyama S, Sato A, Kanaji N, Okimoto T, Kataoka Y, Matsumoto S, Udagawa H, Yoh K, Tsuchihara K, Goto K. A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan). ASCO. Chicago USA JUNE.2-6. 2017
Usui Y, Kirita K, Matsumoto S, Ohe Y, Nishio M, Seto T, Kodani M, Taima K, Hattori Y, Kohno T, Yoh K, Goto K. Detectability of RET fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project: LC-SCRUM-Japan. ESMO 2017. MADRID Sep.8-12. 2017″
Nakamura A, Udagawa H, Matsumoto S, Sugawara S, Shingyoji M, Horiike A, Okamoto I, Hida T, Saeki S, Ohe Y, Ogawara D, Kataoka Y, Miyata Y, Mitsufuji H, Kuyama S, Kanemaru R, ato R, Hirata A, Yoh K, Goto K. Prevalence of NTRK gene fusions in a large cohort of Japanese patients with lung cancer. ESMO asia 2017. Singapore Nov.17-19. 2017
Yoh K, Matsumoto S, Nishino K, Furuya N, Miyamoto S, Oizumi S, Hashimoto S, Sugawara S, Kodani M, Okamoto N, Hara S, Hayashi Y, Motoi N, Ishi G, Goto K. Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: Assessment of PD-L1 expression and tumor mutation burden in non-small cell lung cancer patients treated with immune checkpoint inhibitors. ASCO 2018. Chicago USA JUNE.1-5
Seto T, Matsumoto S, Yoh K, Fujiwara Y, Yokoyama T, Nishino K, Kato K, Sugawara S, Shingoji M, Kodani M, Ohashi K, Tsuchihara K, Goto K. Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer. ASCO 2018. Chicago USA JUNE.1-5
Sakamoto T, Matsumoto S, Sugiyama E, Yoh K, Kobayashi N, Yokoyama T, Shingoji M, Kato K, Aono H, Hara S, Sugawara S, Sekine A, Goto K. Therapeutic and prognostic impact of genetic alterations identified in nationwide genome screening for squamous cell lung cancer (LC-SCRUM-Japan). ASCO 2018. Chicago USA JUNE.1-5
Ogawa Y, Umemura S, Murakami H, Shingoji M, Kobayashi N, Shimokawaji T, Daga H, Seto T, Okamoto N, Aono H, Fujiwara Y, Hara S, Kanaji N, Matsumoto S, Udagawa H, Yoh K, Goto K. Large-scale nationwide genomic screening system for small cell lung cancer in Japan (LC-SCRUM-Japan). ASCO 2018. Chicago USA JUNE.1-5. 2018
Motoi N, Ishii G, Hayashi Y, Tsuta K, Yoh K, Matsumoto S, Goto K. Nationwide Comparative Study Of PD-L1 IHC Assays on Lung Cancer: Initial Report Of LC-SCRUM-IBIS Project. IASLC 19th World Conferece on Lung Cancer Toronto, Canada Sep. 23-26
Furuya N, Umemura S, Udagawa H, Shimokawaji T, Seto T, Daga H, Tsuruno K, Shingyoji M, Hara S, Murakami H, Yokouchi H, Matsumoto S, Goto K. Impact of large-scale nationwide genomic screening project for small cell lung cancer (LC-SCRUM-Japan). ASCO2019.Chicago IL USA May.31-jun4 2019
Kato T, Matsumoto S Umemura S, Yoh K, Nishino K, Daga H, Tsubata Y, Ebi N, Miyamoto S, Shingyoji M, Hashimoto S, Nakagawa T, Hara S, Goto K. Therapeutic and prognostic impacts of specific gene alterations for squamous cell lung cancer: A result of nationwide genome screening in Japan (LC-SCRUM-Japan). ASCO2019.Chicago IL USA May.31-jun4 2019
Oizumi S, Yoh K, Matsumoto S, Miyamoto S, Furuya N, Sasada S, Okamoto N, Hayashi Y, Tsuta K, Motoi N, Ishii G, Goto K. Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker study in LC-SCRUM-Japan. ASCO2019.Chicago IL USA May.31-jun4 2019
Yoh K, Matsumoto S, Kunimasa K, Kodani M, Nishi K, Nakagawa T, Sugawara S, Kato T, Sakakibara-Konishi J, Hayashi Y, Tsuta K, Motoi N, Ishii G, Goto K. The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan. ASCO2019.Chicago IL USA May.31-jun4 2019
Itotani R, Matsumoto S, Udagawa H, Nishino K, Nakachi I, Miyamoto S, Hara S, Kuyama S, Ebi N, Tsubata Y, Shingyoji M, Kato T, Ohe Y, Nishi K, Hashimoto S, Goto K. A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC). ESMO Congress 2019. Barcelona Spain; Sep.27-Oct.10 2019.
Miyamoto S Matsumoto S, Yoh K, Kato T, Nishino K, Sugawara S, Nakao M, Ohe Y, Seto T, Sakakibara-Konishi J, Furuya N, Goto K. linical development of molecular-targeted therapies for non-small cell lung cancer through nationwide genome screening in Japan (LC-SCRUM-Japan). ESMO Congress 2019. Barcelona Spain; Sep.27-Oct.10 2019.
Udagawa H, Matsumoto S, Ohe Y, Satouchi M, Furuya N, Kim Y H, Seto T, Soejima K, Hayakawa D, Kato T, Miyamoto S, Ohashi K, Saeki S, Ohta H, Fujimoto D, Sekine A, Yoh K, Goto K. Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan. WCLC 2019 Congress. Barcelona Spain; Sep.7-10 2019.
Kuo CH, Yoh K, Yang CT, Wang CC, Yen TC, Lin KJ, Ikeda T, Zenke Y, Matsumoto S, Goto K, Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia. ESMO Asia Congress 2019. Singapore; Nov.22-24 2019.
Yoh K, Atagi S, Reck M, Garon E, Ponce Aix S, Moro-Sibilot D, Winfree K, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Nakagawa K, Patient-focused outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC): ESMO Asia Congress 2019. Singapore; Nov.22-24 2019.
Nokihara H, Hida T, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Nakagawa K, Mitsudomi T, Yamamoto N, Kuriki H, Asabe R, Tanaka T, Tamura T. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. 52nd ASCO2016icago IL USA Jun.3-7. 2016
Goto K, Yang JC, Kim DW, Lu S, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner AM, Roychowdhury D, Paolini J, Wilner KD, Wu YL. Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). 52nd ASCO2016. Chicago IL USA Jun.3-7. 2016
Seto T, Yoh K, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Kaname Nosaki, Yoshiko Urata, Niho S, Atsushi Horiike, Kohno T, Matsumoto S, Nomura S, Kuroda S, Sato A, Ohe Y, Yamanaka T, Ohtsu A, Goto K. A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): LURETstudy. 52nd ASCO2016. Chicago IL USA Jun.3-7. 2016
Horiike A, Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Nomura S, Sato A, Ohtsu A, Goto K. LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC). ESMO 2016 Congress. Copenhagen Denmark 7-11 Oct. 2016.
Kim YH, Hida T, Nokihara H, Kondo M, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Nakagawa K, Mitsudomi T, Yamamoto N, Kuriki H, Asabe R, Tanaka T, Tamura T. Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX). IASLC 17th World Conference on Lung Cancer. Vienna Austria December.4-7 2016
Takiguchi Y, Hida T, Nokihara H, Kondo M, Azuma K, Seto T, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Nakagawa K, Mitsudomi T, Yamamoto N, Kuriki H, Asabe R, Tanaka T, Tamura T. Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). ASCO2017. Chicago IL USA June.2-6. 2017
Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Betsuyaku T, Okuno Y, Goto K, Tsuchihara K, Soejima K. Clinical characterization and in silico drug sensitivity prediction model of rare EGFR mutations in non-small cell lung cancer. ASCO2017. Chicago USA JUNE.1-5 （Publication Only)
Kinoshita I, Goda T, Watanabe K, Maemondo M, Oizumi S, Amano T, Hatanaka Y, Matsuno Y, Nishihara H, Asahina H, Harada T, Goto K, Isobe H, Nishimura M, Dosaka H. A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B tria. ESMO 2018 Congress. Munich Germany; Oct.19-23 2018.
Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Kuroda S, Nomura S, Sato A, Tsuchihara K, Kohno T, Matsumoto S, Goto K. LURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer. ESMO 2018 Congress. Munich Germany; Oct.19-23 2018.
Shimokawa M, Nosaki K, Seto T, Ohashi K, Morise M, Fujiwara Y, Sakakibara J, Murakami H, Yano S, Satouchi M, Matsumoto S, Goto K, Yoh K. Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. The European Lung Cancer Congress (ELCC) 2019. Geneva, Switzerland. 10 Apr-13. 2019
Seto T, Nishio M, Hida T, Nokihara H, Morise M, Kim Y H, Azuma K, Takiguchi Y, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Tamura T. Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). ASCO2019.Chicago IL USA May.31-jun4 2019
Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, Tan S W D, Loong H, Bauer T, Kim Y J, Horiike A, Park K, Shah M, McCoach C, Bazhenova L, Seto T, Brose M, Pennell N, Weiss J, Matos I, Peled N, Cho B C, Ohe Y, Reckamp K, Boni V, Satouchi M, Falchook G, Akerley W, Daga H, Sakamoto T, Patel J, Lakhani N, Barlesi F, Burkard M, Zhu V, Garcia V M, Medioni J, Matrana M, Rolfo C, Lee D H, Nechushtan H, Johnson M, Velcheti V, Nishio M, Toyozawa R, Ohashi K, Song L, Han J, Spira A, De Braud F, Rohrberg K S, Takeuchi S, Sakakibara J, Waqar S, Kenmotsu H, Wilson F, Nair B, Olek E, Kherani J, Ebata K, Zhu E, Nguyen M, Yang L, Huang X, Cruickshank S, Rothenberg S, Solomon B, Goto K, Subbiah V, Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. WCLC 2019 Congress. Barcelona Spain; Sep.7-10 2019.
Yanagitani N, Takeuchi S, Murayama T, Yoshimura K, Imai Y, Takahara S, Kawakami T, Seto T. Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET). WCLC 2019 Congress. Barcelona Spain; Sep.7-10 2019.
Zenke Y, Yoh K, Sakakibara-Konishi J, Daga H, Hosomi Y, Nogami N, Okamoto I, Matsumoto S, Kuroda S, Wakabayashi M, Nomura S, Ishi G, Sato A, Tsuboi M, Goto K. Neoadjuvant Ceritinib for Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: SAKULA Trial. WCLC 2019 Congress. Barcelona Spain; Sep.7-10 2019.
松本慎吾、土原一哉、葉清隆、善家義貴、河野隆志:、石井源一郎、蔦幸治、大江裕一郎、山中竹春、後藤功一：A new nationwide genomic screening system for the development of targeted therapies in NSCLC with rare driver mutations / 希少ドライバー変異陽性肺癌の治療開発を目指した全国規模の遺伝子変異スクリーニングシステム. 第12回日本臨床腫瘍学会学術集会、2014.7.17-19
葉清隆、松本慎吾、土原一哉、河野隆志、石井源一郎、蔦幸治、大江裕一郎、山中竹春、後藤功一：Screening for RET and ROS1 fusions in advanced EGFR mutation-negative non-squamous lung cancer（LC-SCRUM-Japan）. 第12回日本臨床腫瘍学会学術集会、 2014.7.17-19
松本慎吾、葉清隆、細見幸生、宿谷威仁、宮田義浩、河野隆志、蔦幸治、石井源一郎、土原一哉、後藤功一：Nationwide genomic screening network for the development of targeted therapies in NSCLC （LC-SCRUM-Japan）非小細胞肺がんの分子標的治療開発を目指した全国規模での遺伝子スクリーニングネットワーク.第13回日本臨床腫瘍学会学術集会、2015.7.16-18
Umemura S. Tsuchihara K. Mimaki S. Matsumoto S. Ishi G. Goto K. Sequencing based molecular profiling of advanced small cell ｌung cancer. 第74回日本癌学会学術総会、2015.10.8-10
Matsumoto S、Yoh K、Tsuchihara K、Kohno T、Tsuta K、Ishi G、Zenke Y、Umemura S、Goto K. Nationwide lung cancer genomic screening project for the development of novel targeted therapies (LC-SCRUM-Japan).第53回日本癌治療学会学術集会、2015.10.29-10.31
阪本智宏、松本慎吾、池村辰之介、井谷英敏、新行内雅斗、小嶋徹、新海正晴、河野隆志、蔦幸治、後藤功一：Detectability of druggable gene fusions by amplicon-based next generation sequencing in LC-SCRUM-Japan. 第14回日本臨床腫瘍学会学術集会、2016.07.28-30
篠田雅宏、梅村茂樹、久山彰一、原聡志、新行内雅斗、津田岳志、原田敏之、塩田哲広、松本慎吾、後藤功一：Development of a nationwide genomic screening project (LC-SCRUM-Japan) for small cell lung cancer for precision medicine. 第14回日本臨床腫瘍学会学術集会、2016.7.28-30
関根朗雅、杉山栄里、松本慎吾、大江裕一郎、岡本勇、小谷昌広、武田晃司、渡辺洋、久山彰一、後藤功一： Clinical features of squamous cell lung cancer with targetable gene alterations identified in LC-SCRUM-Japan. 第15回日本臨床腫瘍学会学術集会、 2017.7.27-29
池田喬哉、大橋圭明、関根朗雅、大江裕一郎、津田岳志、片岡裕貴、原聡志、岡本紀雄、小谷昌広、松本慎吾、後藤功一：Clinical significance of TMB estimated by smallsized-targeted NGS as a predictive marker of ICIs for NSCLC. 第16回日本臨床腫瘍学会、2018.7.19-21
小谷昌広、葉清隆、松本慎吾、國政啓、西耕一、中川拓、菅原俊一、加藤智浩、榊原純、蔦幸治、林雄一郎、元井紀子、石井源一郎、後藤功一:Immuno-oncology biomarker study in non-small cell lung cancer harboring oncogenic driver alterations: LC-SCRUM-IBIS.第17回日本臨床腫瘍学会学術集会、2019.7.18-20
駄賀晴子、松本慎吾、梅村茂樹、葉清隆、加藤晃史、西野和美、津端由佳里、海老規之、宮本信吾、新行内雅斗、田幡江利子、中川拓、原聡志、後藤功一：Therapeutic and prognostic impacts of specific gene alterations for squamous cell lung cancer in LC-SCRUM-Japan. 第17回日本臨床腫瘍学会学術集会、2019.7.18-20
國政啓、松本慎吾、葉清隆、加藤晃史、宮本信吾、菅原俊一、中尾美香、大江裕一郎、瀬戸貴司、榊原純、古屋直樹、後藤功一:Clinical development of molecular-targeted therapies for non-small cell lung cancer through LC-SCRUM-Japan.第17回日本臨床腫瘍学会学術集会、2019.7.18-20
葉清隆、瀬戸貴司、里内美弥子、西尾誠人、山本昇、村上晴泰、野上尚之、山中竹春、後藤功一：LURET study: A phase II study of vandetanib, RET inhibitor in patients with advanced RET fusion-positive NSCLC．第13回日本臨床腫瘍学会、2015.7.16-18
Urata Y、Yoh K、Seto T、Satouchi M、Nishio M、Yamamoto N、Murakami H、Nogami N、Nomura S、Goto K. A phase II study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC):LURET study. 第14回日本臨床腫瘍学会学術集会
Seto T、Yang CH、Wu YL、Kim DW、Yamamoto N、Takahashi T、Yamanaka T、Kemner A、Paolini J、Goto K. A phase II study of crizotinib in East Asian patients with ROS1+ advanced non-small cell lung cancer (NSCLC). 第14回日本臨床腫瘍学会学術総会、2016.7.28-30
善家義貴：SAKULA trial: A phase II study of neoadjuvant ALK inhibitor followed by surgery for ALK-positive locally advanced NSCLC. 第14回日本臨床腫瘍学会学術集会、2016.7.28-30
後藤功一、James CH Yang、Dong-Wan Kim、Shun Lu、Jianying Zhou、瀬戸貴司、Jin-Ji Yang、Jolanda Paolini、Debasish Roychowdhury、Yi-Long Wu ：Phase II study of Crizotinib in East Asian patients (pts) with ROS1+advanced non-small cell lung cancer (NSCLC). 第15回日本臨床腫瘍学会学術集会 、2017.7.27-29
